Psychiatry

News

One of J&J's blockbuster depression hopes has flamed out

Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.

News

Supernus reports less than super data for depression drug

Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial.

News

J&J's Spravato gets another lift with new FDA approval

Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression.

News

Boehringer drug for brain fog in schizophrenia fails trial

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

Patients

hands holding paper head representing protecting the mind

Keeping stigma out of it: Personalising the mental health co...

Thursday 10th October was World Mental Health Day, focused this year on ‘mental health at work’.

News

Talkiatry co-founders Dr Georgia Gaveras (l) and Robert Krayn (r)

Biogen, Talkiatry team up on postpartum depression

Telehealth company Talkiatry has partnered with Biogen to expand its support service for women who develop postpartum depression (PPD) in a move that could help drive uptake of the latter's

One of J&J's blockbuster depression hopes has flamed out

Supernus reports less than super data for depression drug

J&J's Spravato gets another lift with new FDA approval

Boehringer drug for brain fog in schizophrenia fails trial

Keeping stigma out of it: Personalising the mental health co...

Biogen, Talkiatry team up on postpartum depression

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Psychiatry

Editor's Picks